Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PerkinElmer Inc.
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Birmingham, UK-based The Binding Site and its 1,100 employees will now fall under Thermo Fisher’s expanding umbrella.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Technologies
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Analytica of Branford, Inc.
- Arnel Inc.
- BioLegend, Inc.
- Haoyuan Biotech Co. Ltd.
- Immunodiagnostic Systems Holdings PLC
- Opto Technology, Inc.
- Perten Instruments
- SYM-BIO Lifescience
- Tulip Diagnostics Private Limited
- Wallac Oy
- Vanadis Diagnostics, AB
- Oxford Immunotec Global PLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.